A Suicide Gene Therapy Combining the Improvement of Cyclophosphamide Tumor Cytotoxicity and the Development of an Anti-Tumor Immune Response.   Touati W, Tran T, Seguin J, Diry M, Jean-Pierre F,

Prognostic factors in patients with advanced renal cell carcinoma treated with VEGF-targeted agents.   Vano YA, Tartour E, Fournier LS, Beuselinck B, Mejean A, Oudard S. Expert Rev Anticancer Ther.

[MET signalling pathway and its therapeutic implications in gastrointestinal cancers]. [Article in French] Zaanan A, Laurent-Puig P, Taieb J. Bull. Cancer 2014 Jan The MET receptor tyrosine kinase and its

Phase I study of elisidepsin (Irvalec®) in combination with carboplatin or gemcitabine in patients with advanced malignancies. Goldwasser F1, Faivre S, Alexandre J, Coronado C, Fernández-García EM, Kahatt CM, Paramio

[Oncology and other specialities Centre of the Georges-Pompidou European hospital: a model of unifying pneumology and oncology network].   [Article in French] Le Pimpec-Barthes F, Sors H, Oudard S, Riquet

Drug safety evaluation of sorafenib for treatment of solid tumors: consequences for the risk assessment and management of cancer patients. Huillard O, Boissier E, Blanchet B, Thomas-Schoemann A, Cessot A,

ERBB2 gene as a potential therapeutic target in small bowel adenocarcinoma. Laforest A, Aparicio T, Zaanan A, Silva FP, Didelot A, Desbeaux A, Le Corre D, Benhaim L, Pallier K,

Adrenocortical carcinomas (ACCs) are aggressive cancers originating in the cortex of the adrenal gland. Despite overall poor prognosis, ACC outcome is heterogeneous. We performed exome sequencing and SNP array analysis